The quarter was solid against the company’s modest setup, but there is no reliable published consensus here to substantiate a clean beat. Revenue reached $265.7 million, including $5.9 million from Breathe Right, while organic revenue grew 3.2%—above the company’s full-year 1%-3% organic-growth framework. The underlying result was therefore better than a low-growth baseline, though the filing’s “exceeded expectations” claim is management’s framing rather than independently verifiable consensus. (Q1 Performance Highlights; Organic Revenue Change reconciliation)
| Metric | Q1 FY27 | Q1 FY26 | Change / context |
|---|---|---|---|
| Revenue | $265.7M | $249.5M | +6.5% |
| Organic revenue | $259.8M | $251.6M | +3.2% |
| Adjusted EBITDA | $84.1M | $79.6M | +5.5% |
| Adjusted EBITDA margin | 31.6% | 31.9% | Down 0.3 pts |
| Adjusted diluted EPS | $0.98 | $0.95 | +3.2% |
| GAAP diluted EPS | $0.61 | $0.95 | Down $0.34 |
| Adjusted free cash flow | $83.7M | $78.2M | +7.1% |
| Net debt | ~$2.0B | — | Higher after acquisitions |
The quality of the earnings mix was weaker than the headline growth suggests. Adjusted gross margin fell to 55.0% from 56.2%, and adjusted EBITDA margin edged down to 31.6% from 31.9%. Adjusted EPS rose only because the company excluded $17.3 million of after-tax items, including Pillar5 remediation costs and $12.8 million of acquisition expenses; GAAP EPS declined to $0.61. (Consolidated Financial Summary; Adjusted Gross Margin reconciliation; Adjusted Net Income & Adjusted Diluted EPS reconciliation)
The acquisition-led outlook is higher, but it is not an organic reset. Fiscal 2027 revenue guidance moved to $1.290-$1.315 billion from $1.100-$1.121 billion, primarily reflecting roughly $190 million of acquired revenue from Breathe Right and LaCorium. Adjusted EPS rose to $4.55-$4.65 from $4.42-$4.51, while adjusted free-cash-flow guidance increased to at least $270 million from at least $250 million. The strategic picture improves through scale and diversification, but the core business is still guided to only 1%-3% organic growth. (Updated FY27 Outlook; Latest FY27 Financial Outlook)
The main trade-off is greater earnings scale versus materially higher execution and balance-sheet risk. Net debt was approximately $2.0 billion after the Breathe Right transaction, funded with new debt, and management now prioritizes debt reduction. Eye-care supply also remains “dynamic,” with Clear Eyes variability and Pillar5 capacity work still limiting confidence in a full recovery. Strong cash generation helps, but the quarter does not yet prove that the acquisitions or manufacturing investments will produce the promised margin and growth benefits. (Free Cash Flow Comments; Eye Care Supply Remains Dynamic; Deals Successfully Closed; Integrations on Track)
Read the original 8-K on SEC EDGAR ↗